| Title: | Evaluation of 116 Patients with IPF commenced on anti-fibrotic treatment therapies in Cork University Hospital |
|---|---|
| Author(s): | B.Bowen M.Henry |
| Institution: | Cork University Hospital |
| Poster: | Click to view poster |
| Category: | ILD |
| Abstract: | There are two approved anti- fibrotic treatments for IPF, pirfenidone (P) and nintedanib (N) but some patients need to stop or switch medications due to side effects. In large studies, both treatments slow the progression of IPF by approximately 50 per cent based on lung function measurement. The aim of this study was to evaluate the medication treatments and side effects on our cohort of patients with IPF over a two and a half year period. Consecutive patients with mild/moderate IPF (FVC>50% predicted, DLCO>35% predicted) prescribed pirfenidone or nintedanib at the ILD clinic in Cork University Hospital were analysed.116 patients commenced on either treatment from January 2019 to June 2021 were assessed. N =116 No. Prescribed: Pirfenidone 45 (38%) ,Nintedanib 71 (61%) Switched to other anti-fibrotic: Pirfenidone to Nintedanib,10 (22.2%) Reason for switch:Six (13.3%) due to nausea, vomiting, indigestion, generally unwell, loss of appetite, lethargy, wanting to go out in the sun Four (8.8%) due to decline in lung function Switched from Nintedanib to Pirfenidone 9 (12.6%)Seven (9.8%) due to severe nausea, vomiting, stomach issues, diarrhoea, severe itching. Two (2.8%) due to raised LFT’s 55 (77.5%) 16 (22.5%) Full dose tolerated : Pirfenidone 43 (95.5%), Nintedanib 55 (77.5%) Reduced dose: Pirfenidone 2 (4.4%), Nintedanib 16 (22.5%) With education, awareness and a patient centered approach, potential dose adjustment, monitoring and symptom management is crucial to maintain adherence to the therapies |
